Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0VGDC)

• Drug Name: ARRY-382 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 67259771
  TTD Drug ID: DM0VGDC

Molecule-Related Drug Atlas

Drug(s) Targeting Colony stimulating factor-1 receptor (CSF-1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG7155	DM8JMNL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
MCS-110	DM0CL4I	Bone metastases	2D50	Phase 2	[4]
JNJ-40346527	DM219SF	Hodgkin lymphoma	2B30	Phase 2	[5]
PD-360324	DM6F5EV	Rheumatoid arthritis	FA20	Phase 2	[6]
FPA-008	DM3ZN6Y	Autoimmune diabetes	5A10	Phase 1/2	[7]
AMG 820	DMB6Q19	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
IMC-CS4	DMUYN26	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]

Drug(s) Targeting Macrophage colony-stimulating factor 1 receptor (CSF1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[8]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[1]
BLZ-945	DMG1LVA	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[1]
Cabiralizumab	DMGE058	Pancreatic cancer	2C10	Phase 2	[9]
AMB-05X	DM958C5	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[10]
FPA-008	DM3ZN6Y	Autoimmune diabetes	5A10	Phase 1/2	[11]
DCC-3014	DMHW289	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]
DCC-3014	DMHW289	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[12]
PLX7486	DM0IVGU	Pancreatic cancer	2C10	Phase 1	[1]
TPX-0022	DMC2IJN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Colony stimulating factor-1 receptor (CSF-1R)	TT731LW	E9PEK4_HUMAN	Modulator	[2]
Macrophage colony-stimulating factor 1 receptor (CSF1R)	TT7MRDV	CSF1R_HUMAN	Inhibitor	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Company report (Array)
• [3] Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25(6):846-59.
• [4] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [5] An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clin Cancer Res. 2015 Apr 15;21(8):1843-50.
• [6] Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus.Clin Exp Immunol.2016 Feb;183(2):258-70.
• [7] Company report (Five Prime Therapeutics)
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Clinical pipeline report, company report or official report of AmMax Bio
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
• [13] Clinical pipeline report, company report or official report of Turning Point Therapeutics.